Document Detail


The first case report of sulfonylurea use in a woman with permanent neonatal diabetes mellitus due to KCNJ11 mutation during a high-risk pregnancy.
MedLine Citation:
PMID:  20466780     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Sulfonylureas (SUs) were proven to be more effective than insulin in most Kir6.2 permanent neonatal diabetes mellitus (PNDM) patients. We report SU use during pregnancy in PNDM. A woman with the R201H Kir6.2 mutation became pregnant at the age of 37. The patient had been on glipizide 30 mg for 3 yr; her glycosylated hemoglobin level was 5.8%. She was diagnosed with chronic diabetes complications and a congenital defect of the urogenitary tract-a bicornuate uterus with septum. Because the effect of SU on fetal development is uncertain, she was switched to insulin after the pregnancy diagnosis; however, the subsequent glycemic control was unsatisfactory, with episodes of hyper- and hypoglycemia. Thus, in the second trimester, the patient was transferred to SU (glibenclamide, 40 mg), which resulted in stabilization of glycemic control; glycosylated hemoglobin in the third trimester was 5.8%. Prenatal genetic testing excluded the Kir6.2 R201H mutation in the fetus. A preterm cesarean delivery was carried out in the 35th week. The Apgar score of the newborn boy (weight, 3010 g; 75th percentile) was 8 at 1 min. He presented with hypoglycemia, transient tachypnea of the newborn, and hyperbilirubinemia. The recovery was uneventful. No birth defects were recorded. His development at the ninth month of life was normal. In summary, we show a high-risk pregnancy in long-term PNDM that despite perinatal complications ended with the birth of a healthy child. SUs, which seem to constitute an alternative to insulin during pregnancy in Kir6.2-related PNDM, were used during the conception period and most of the second and third trimesters.
Authors:
Tomasz Klupa; Elzbieta Kozek; Natalia Nowak; Katarzyna Cyganek; Agnieszka Gach; Tomasz Milewicz; Krzysztof Czajkowski; Justyna Tolloczko; Wojciech Mlynarski; Maciej T Malecki
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-05-13
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  95     ISSN:  1945-7197     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-05     Completed Date:  2010-08-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3599-604     Citation Subset:  AIM; IM    
Affiliation:
Department of Metabolic Diseases, Jagiellonian University Medical College, University Hospital, 15 Kopernika Street, 31-501 Krakow, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Diabetes Mellitus, Type 1 / drug therapy*,  genetics
Female
Humans
Hypoglycemic Agents / therapeutic use
Potassium Channels, Inwardly Rectifying / genetics*
Pregnancy
Pregnancy in Diabetics / drug therapy*,  genetics
Pregnancy, High-Risk / genetics
Sulfonylurea Compounds / therapeutic use*
Chemical
Reg. No./Substance:
0/Hypoglycemic Agents; 0/Kir6.2 channel; 0/Potassium Channels, Inwardly Rectifying; 0/Sulfonylurea Compounds

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Kinetics of satratoxin g tissue distribution and excretion following intranasal exposure in the mous...
Next Document:  Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) P...